Acute myeloid leukemia
Drug research and approvals for acute myeloid leukemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 607 studies of acute myeloid leukemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 88 drug trials for it since 2013, and FDA has 22 approved and 156 open orphan designations naming it.
- Recruiting worldwide: 607
- Trials authorized in Canada: 88
- FDA orphan approvals: 22
- EU medicines: 0
Recruiting Now
Newest start dates first, of 607 recruiting on ClinicalTrials.gov ↗- Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for…NCT06930352 · Phase 2 · Uma Borate · starts Jan 15, 2027
- A Home-Based Exercise Intervention (CAREFit-BMT) in Improving Heart Function Among Patients With High Risk Acute…NCT07616921 · Not applicable · University of Washington · starts Dec 1, 2026
- FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid LeukemiaNCT07645469 · Phase 1 · Fred Hutchinson Cancer Center · starts Dec 1, 2026
- ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDSNCT07617363 · Phase 1 · Washington University School of Medicine · starts Nov 30, 2026
- Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaNCT07783100 · Phase 2 · The First Affiliated Hospital of Xiamen University · starts Nov 11, 2026
- The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic…NCT07912684 · Not applicable · Gruppo Italiano Malattie EMatologiche dell'Adulto · starts Nov 10, 2026
- Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic…NCT07582172 · Phase 2 · City of Hope Medical Center · starts Nov 5, 2026
- A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML)…NCT07925190 · Phase 3 · Beijing InnoCare Pharma Tech Co., Ltd. · starts Nov 3, 2026
- Allogeneic iNKT Cell Therapy (agenT-797) After SCTNCT07758218 · Phase 1 · University of Wisconsin, Madison · starts Nov 1, 2026
- Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received VenetoclaxNCT07471841 · Phase 2 · Timothy Pardee · starts Nov 1, 2026
Trials Authorized in Canada
The 10 newest of 88; search them all in Canada trials| Oct 14, 2026 | A phase I/ib, multi-center, open-label, dose escalation and dose expansion study of fvy281 as monotherapy in adult participants with relapsed/refractory acute…FVY281 / AZACITIDINE | Novartis Pharmaceuticals Corporation | Pending |
| Sep 29, 2026 | A two-part, phase 2b/phase 3 double-blinded, randomized study of ipn60340 in combination with azacitidine and venetoclax versus placebo in combination with…IPN60340 | Ipsen | Pending |
| Sep 25, 2026 | A phase 1/2, dose optimization and dose expansion, multicenter, open-label study to evaluate the safety, pharmacokinetics, and efficacy of menin inhibitor…VICRIMENIB (S243249, BN104) | Servier | Pending |
| May 27, 2026 | A phase 1b study of the safety and pharmacokinetics of pivekimab sunirine in pediatric subjects with relapsed or refractory acute myeloid leukemia (aml)PIVEKIMAB SUNIRINE (IMGN-632) | AbbVie | Pending |
| May 26, 2026 | A phase 2 trial of gilteritinib in combination with azacitidine and venetoclax to overcome venetoclax resistance in patients with relapsed/refractory flt3-wild…GILTERITINIB | BC CANCER, PART OF THE PROVINCIAL HEALTH SERVICES AUTHORITY | Pending |
| Mar 26, 2026 | A randomized phase II study of venetoclax and hma-based therapies for the treatment of older and unfit adults with newly diagnosed flt3-mutated acute myeloid…VENETOCLAX (ABT-199) / GILTERITINIB (ASP2215) | CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY | Ongoing |
| Dec 15, 2025 | A phase 3, randomized, double-blind, placebo-controlled study of revumenib in combination with intensive chemotherapy in participants with newly diagnosed aml…REVUMENIB (SNDX-5613) / CYTARABINE / DAUNORUBICIN / IDARUBICIN | Syndax Pharmaceuticals | Pending |
| Aug 28, 2025 | Phase 3 randomized, double-blind, placebo-controlled studies assessing ziftomenib in combination with either standard of care nonintensive…ZIFTOMENIB / VENETOCLAX / AZACITIDINE / DAUNORUBICIN / CYTARABINE | Kura Oncology | Ongoing |
| May 23, 2025 | A phase 1 study of tak-243 for relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes with increased blastsTAK-243 | UNIVERSITY HEALTH NETWORK | Ongoing |
| Feb 25, 2025 | A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed…BLEXIMENIB (JNJ-75276617) | Johnson & Johnson | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 178| May 13, 2026 | Inqoviin combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have… | Taiho Oncology Inc. | Approved |
| Nov 13, 2025 | Komziftitreatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who… | Kura Oncology, Inc. | Approved |
| Oct 24, 2025 | Revuforjtreatment of relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric… | Syndax Pharmaceuticals, Inc. | Approved |
| Jan 21, 2025 | Grafapexin combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric… | Medac GmbH | Approved |
| Nov 15, 2024 | Revuforjtreatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric… | Syndax Pharmaceuticals, Inc. | Approved |
| Jul 20, 2023 | Vanflytain combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following… | Daiichi Sankyo, Inc. | Approved |
| Dec 1, 2022 | Rezlidhiatreatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1)… | Rigel Pharmaceuticals, Inc. | Approved |
| May 25, 2022 | TibsovoIn combination with azacitidine or as monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible… | Servier Pharmaceuticals LLC | Approved |
| Mar 30, 2021 | VYXEOS ; Vyxeos ; Vyxeostreatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults… | Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals Company) | Approved |
| Sep 1, 2020 | ONUREGONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or… | Bristol-Myers Squibb | Approved |
| Jun 16, 2020 | MylotargMylotarg¿ is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and pediatric patients 1 month… | Wyeth Pharmaceuticals, Inc., a Pfizer Company | Approved |
| May 2, 2019 | TIBSOVOTIBSOVO is indicated for the treatment of newly-diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1)… | Servier Pharmaceuticals LLC | Approved |
| Nov 28, 2018 | XOSPATAXOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like… | Astellas Pharma US, Inc. | Approved |
| Nov 21, 2018 | DAURISMODAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult… | Pfizer, Inc. | Approved |
| Nov 21, 2018 | VENCLEXTAVENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute… | AbbVie Inc. | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA